BCL2 and glioblastoma: In keeping with the expectation, c-MET inhibition along with dual Bcl-2/Bcl-xL inhibition causes synthetic lethality in stem-like and established GBM cells, which is pharmacologically exemplified by the drug combination of ABT263 and Crizotinib, two drugs that are tested or used in patients already.